Logo image of PTCT

PTC THERAPEUTICS INC (PTCT) Stock Price, Quote, News and Overview

NASDAQ:PTCT - Nasdaq - US69366J2006 - Common Stock - Currency: USD

44.74  -1.58 (-3.41%)

After market: 44.2 -0.54 (-1.21%)

PTCT Quote, Performance and Key Statistics

PTC THERAPEUTICS INC

NASDAQ:PTCT (7/25/2025, 8:18:26 PM)

After market: 44.2 -0.54 (-1.21%)

44.74

-1.58 (-3.41%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High58.38
52 Week Low29.02
Market Cap3.55B
Shares79.26M
Float77.30M
Yearly DividendN/A
Dividend YieldN/A
PE8.55
Fwd PEN/A
Earnings (Next)07-31 2025-07-31/amc
IPO06-20 2013-06-20


PTCT short term performance overview.The bars show the price performance of PTCT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6 -8

PTCT long term performance overview.The bars show the price performance of PTCT in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30

The current stock price of PTCT is 44.74 USD. In the past month the price decreased by -9.71%. In the past year, price increased by 31.24%.

PTC THERAPEUTICS INC / PTCT Daily stock chart

PTCT Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.53 336.11B
AMGN AMGEN INC 14.77 164.85B
GILD GILEAD SCIENCES INC 15.01 144.54B
VRTX VERTEX PHARMACEUTICALS INC N/A 120.61B
REGN REGENERON PHARMACEUTICALS 12.71 60.80B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 42.87B
ARGX ARGENX SE - ADR 102.95 36.15B
ONC BEONE MEDICINES LTD-ADR 7.43 31.54B
BNTX BIONTECH SE-ADR N/A 27.72B
SMMT SUMMIT THERAPEUTICS INC N/A 21.29B
INSM INSMED INC N/A 19.72B
BIIB BIOGEN INC 8.31 19.27B

About PTCT

Company Profile

PTCT logo image PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is headquartered in Warren, New Jersey and currently employs 939 full-time employees. The company went IPO on 2013-06-20. The firm is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).

Company Info

PTC THERAPEUTICS INC

500 Warren Corporate Center Drive

WARREN NEW JERSEY 07080 US

CEO: Stuart W. Peltz

Employees: 939

PTCT Company Website

PTCT Investor Relations

Phone: 19082227000

PTC THERAPEUTICS INC / PTCT FAQ

What is the stock price of PTC THERAPEUTICS INC today?

The current stock price of PTCT is 44.74 USD. The price decreased by -3.41% in the last trading session.


What is the ticker symbol for PTC THERAPEUTICS INC stock?

The exchange symbol of PTC THERAPEUTICS INC is PTCT and it is listed on the Nasdaq exchange.


On which exchange is PTCT stock listed?

PTCT stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for PTC THERAPEUTICS INC stock?

23 analysts have analysed PTCT and the average price target is 63.78 USD. This implies a price increase of 42.57% is expected in the next year compared to the current price of 44.74. Check the PTC THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PTC THERAPEUTICS INC worth?

PTC THERAPEUTICS INC (PTCT) has a market capitalization of 3.55B USD. This makes PTCT a Mid Cap stock.


How many employees does PTC THERAPEUTICS INC have?

PTC THERAPEUTICS INC (PTCT) currently has 939 employees.


What are the support and resistance levels for PTC THERAPEUTICS INC (PTCT) stock?

PTC THERAPEUTICS INC (PTCT) has a support level at 44.73 and a resistance level at 47.39. Check the full technical report for a detailed analysis of PTCT support and resistance levels.


Is PTC THERAPEUTICS INC (PTCT) expected to grow?

The Revenue of PTC THERAPEUTICS INC (PTCT) is expected to grow by 115.74% in the next year. Check the estimates tab for more information on the PTCT EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PTC THERAPEUTICS INC (PTCT) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PTC THERAPEUTICS INC (PTCT) stock pay dividends?

PTCT does not pay a dividend.


When does PTC THERAPEUTICS INC (PTCT) report earnings?

PTC THERAPEUTICS INC (PTCT) will report earnings on 2025-07-31, after the market close.


What is the Price/Earnings (PE) ratio of PTC THERAPEUTICS INC (PTCT)?

The PE ratio for PTC THERAPEUTICS INC (PTCT) is 8.55. This is based on the reported non-GAAP earnings per share of 5.23 and the current share price of 44.74 USD. Check the full fundamental report for a full analysis of the valuation metrics for PTCT.


What is the Short Interest ratio of PTC THERAPEUTICS INC (PTCT) stock?

The outstanding short interest for PTC THERAPEUTICS INC (PTCT) is 7.76% of its float. Check the ownership tab for more information on the PTCT short interest.


PTCT Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to PTCT. When comparing the yearly performance of all stocks, PTCT turns out to be only a medium performer in the overall market: it outperformed 62.8% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PTCT Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to PTCT. Both the profitability and the financial health of PTCT get a neutral evaluation. Nothing too spectacular is happening here.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PTCT Financial Highlights

Over the last trailing twelve months PTCT reported a non-GAAP Earnings per Share(EPS) of 5.23. The EPS increased by 189.25% compared to the year before.


Industry RankSector Rank
PM (TTM) 33.55%
ROA 22.4%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%936.67%
Sales Q2Q%459.73%
EPS 1Y (TTM)189.25%
Revenue 1Y (TTM)91.12%

PTCT Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to PTCT. The Buy consensus is the average rating of analysts ratings from 23 analysts.

For the next year, analysts expect an EPS growth of 215.08% and a revenue growth 115.74% for PTCT


Ownership
Inst Owners100.78%
Ins Owners0.63%
Short Float %7.76%
Short Ratio4.62
Analysts
Analysts78.26
Price Target63.78 (42.56%)
EPS Next Y215.08%
Revenue Next Year115.74%